Literature DB >> 25385865

Circulating serum markers and QRS scar score in Chagas cardiomyopathy.

Eva H Clark1, Morgan A Marks2, Robert H Gilman2, Antonio B Fernandez2, Thomas C Crawford2, Aaron M Samuels2, Alicia I Hidron2, Gerson Galdos-Cardenas2, Gilberto Silvio Menacho-Mendez2, Ricardo W Bozo-Gutierrez2, Diana L Martin2, Caryn Bern2.   

Abstract

Approximately 8 million people have Trypanosoma cruzi infection, and nearly 30% will manifest Chagas cardiomyopathy (CC). Identification of reliable early indicators of CC risk would enable prioritization of treatment to those with the highest probability of future disease. Serum markers and electrocardiogram (EKG) changes were measured in 68 T. cruzi-infected individuals in various stages of cardiac disease and 17 individuals without T. cruzi infection or cardiac disease. T. cruzi-infected individuals were assigned to stage A (normal EKG/chest x-ray [CXR]), B (abnormal EKG/normal CXR), or C (abnormal EKG/cardiac structural changes). Ten serum markers were measured using enzyme-linked immunosorbent assay (ELISA)/Luminex, and QRS scores were calculated. Higher concentrations of transforming growth factor-β1 (TGFβ1), and TGFβ2 were associated with stage B compared with stage A. Matrix Metalloproteinase 2 (MMP2), Tissue Inhibitors of MMP 1, QRS score, and Brain Natriuretic Protein rose progressively with increasing CC severity. Elevated levels of several markers of cardiac damage and inflammation are seen in early CC and warrant additional evaluation in longitudinal studies. © The American Society of Tropical Medicine and Hygiene.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25385865      PMCID: PMC4347387          DOI: 10.4269/ajtmh.14-0246

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  43 in total

Review 1.  Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts.

Authors:  G R Grotendorst
Journal:  Cytokine Growth Factor Rev       Date:  1997-09       Impact factor: 7.638

Review 2.  ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).

Authors:  Sharon Ann Hunt
Journal:  J Am Coll Cardiol       Date:  2005-09-20       Impact factor: 24.094

3.  Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial.

Authors:  Rodolfo Viotti; Carlos Vigliano; Bruno Lococo; Graciela Bertocchi; Marcos Petti; María Gabriela Alvarez; Miriam Postan; Alejandro Armenti
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

Review 4.  Predictors of mortality in chronic Chagas disease: a systematic review of observational studies.

Authors:  Anis Rassi; Anis Rassi; Sérgio G Rassi
Journal:  Circulation       Date:  2007-03-06       Impact factor: 29.690

Review 5.  Echocardiography in Chagas heart disease.

Authors:  Harry Acquatella
Journal:  Circulation       Date:  2007-03-06       Impact factor: 29.690

Review 6.  Pathogenesis of chronic Chagas heart disease.

Authors:  Jose Antonio Marin-Neto; Edécio Cunha-Neto; Benedito C Maciel; Marcus V Simões
Journal:  Circulation       Date:  2007-03-06       Impact factor: 29.690

Review 7.  Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function.

Authors:  Francis G Spinale
Journal:  Physiol Rev       Date:  2007-10       Impact factor: 37.312

Review 8.  Evaluation and treatment of chagas disease in the United States: a systematic review.

Authors:  Caryn Bern; Susan P Montgomery; Barbara L Herwaldt; Anis Rassi; Jose Antonio Marin-Neto; Roberto O Dantas; James H Maguire; Harry Acquatella; Carlos Morillo; Louis V Kirchhoff; Robert H Gilman; Pedro A Reyes; Roberto Salvatella; Anne C Moore
Journal:  JAMA       Date:  2007-11-14       Impact factor: 56.272

9.  Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure.

Authors:  Norimichi Koitabashi; Masashi Arai; Kazuo Niwano; Atai Watanabe; Michiko Endoh; Masahiko Suguta; Tomoyuki Yokoyama; Hiroshi Tada; Takuji Toyama; Hitoshi Adachi; Shigeto Naito; Shigeru Oshima; Takashi Nishida; Satoshi Kubota; Masaharu Takigawa; Masahiko Kurabayashi
Journal:  Eur J Heart Fail       Date:  2008-03-11       Impact factor: 15.534

10.  Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors.

Authors:  Ester C Sabino; Antonio L Ribeiro; Vera M C Salemi; Claudia Di Lorenzo Oliveira; Andre P Antunes; Marcia M Menezes; Barbara M Ianni; Luciano Nastari; Fabio Fernandes; Giuseppina M Patavino; Vandana Sachdev; Ligia Capuani; Cesar de Almeida-Neto; Danielle M Carrick; David Wright; Katherine Kavounis; Thelma T Goncalez; Anna Barbara Carneiro-Proietti; Brian Custer; Michael P Busch; Edward L Murphy
Journal:  Circulation       Date:  2013-02-07       Impact factor: 29.690

View more
  8 in total

1.  Toxicological, Enzymatic, and Molecular Assessment of the Insecticide Susceptibility Profile of Triatoma infestans (Hemiptera: Reduviidae, Triatominae) Populations From Rural Communities of Santa Cruz, Bolivia.

Authors:  Pablo L Santo-Orihuela; Claudia V Vassena; Guillermo Carvajal; Eva Clark; Silvio Menacho; Ricardo Bozo; Robert H Gilman; Caryn Bern; Paula L Marcet
Journal:  J Med Entomol       Date:  2017-01-01       Impact factor: 2.278

2.  Correlation of transforming growth factor-β1 and tumour necrosis factor levels with left ventricular function in Chagas disease.

Authors:  Eduardo Ov Curvo; Roberto R Ferreira; Fabiana S Madeira; Gabriel F Alves; Mayara C Chambela; Veronica G Mendes; Luiz Henrique C Sangenis; Mariana C Waghabi; Roberto M Saraiva
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-02-19       Impact factor: 2.743

3.  TGF-β Polymorphisms Are a Risk Factor for Chagas Disease.

Authors:  Roberto Rodrigues Ferreira; Fabiana da Silva Madeira; Gabriel Farias Alves; Mayara da Costa Chambela; Eduardo de Oliveira Vaz Curvo; Aline Dos Santos Moreira; Renata Almeida de Sá; Leila Mendonça-Lima; Pedro Hernan Cabello; Sabine Bailly; Jean-Jacques Feige; Tania Cremonini Araujo-Jorge; Roberto Magalhães Saraiva; Mariana Caldas Waghabi
Journal:  Dis Markers       Date:  2018-02-18       Impact factor: 3.434

4.  Genetic association study of NLRP1, CARD, and CASP1 inflammasome genes with chronic Chagas cardiomyopathy among Trypanosoma cruzi seropositive patients in Bolivia.

Authors:  Steven J Clipman; Josephine Henderson-Frost; Katherine Y Fu; Caryn Bern; Jorge Flores; Robert H Gilman
Journal:  PLoS One       Date:  2018-02-13       Impact factor: 3.240

5.  Cardiac Fibrosis and Changes in Left Ventricle Function in Patients with Chronic Chagas Heart Disease.

Authors:  João Bosco de Figueiredo Santos; Ilan Gottlieb; Eduardo Marinho Tassi; Gabriel Cordeiro Camargo; Jacob Atié; Sérgio Salles Xavier; Roberto Coury Pedrosa; Roberto Magalhães Saraiva
Journal:  Arq Bras Cardiol       Date:  2021-12       Impact factor: 2.000

6.  Matrix Metalloproteinase 2 and 9 Enzymatic Activities are Selectively Increased in the Myocardium of Chronic Chagas Disease Cardiomyopathy Patients: Role of TIMPs.

Authors:  Monique Andrade Baron; Ludmila Rodrigues Pinto Ferreira; Priscila Camillo Teixeira; Ana Iochabel Soares Moretti; Ronaldo Honorato Barros Santos; Amanda Farage Frade; Andréia Kuramoto; Victor Debbas; Luiz Alberto Benvenuti; Fabio Antônio Gaiotto; Fernando Bacal; Pablo Pomerantzeff; Christophe Chevillard; Jorge Kalil; Edecio Cunha-Neto
Journal:  Front Cell Infect Microbiol       Date:  2022-03-17       Impact factor: 5.293

7.  Call for Consensus in the Evaluation of Circulating Matrix Metalloproteinases in Chagas Disease.

Authors:  Norma Bautista-López; Richard Schulz
Journal:  Am J Trop Med Hyg       Date:  2022-07-05       Impact factor: 3.707

8.  Progression of Baseline Electrocardiogram Abnormalities in Chagas Patients Undergoing Antitrypanosomal Treatment.

Authors:  Jonathan Soverow; Salvador Hernandez; Daniel Sanchez; Colin Forsyth; Carmen A Flores; Gracia Viana; Sheba Meymandi
Journal:  Open Forum Infect Dis       Date:  2019-01-19       Impact factor: 3.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.